GlassScriptPhysician profile
Gary I Weingarden
NPI 1477501724
$2,357.96
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $545 · 2021: $581 · 2022: $409.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $529.81 | 2019-2021 | |
| Abbott Laboratories | $362.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $260.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $126.16 | 2019-2022 | |
| Amgen INC. | $100.59 | 2020-2022 | |
| Pfizer INC. | $100.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $97.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.34 | 2019-2021 | |
| Astellas Pharma US INC | $77.57 | 2019-2021 | |
| Edwards Lifesciences Corporation | $56.91 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $56.50 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $52.50 | 2019-2020 | |
| Boston Scientific Corporation | $51.64 | 2019-2020 | |
| Bardy Diagnostics, INC. | $37.80 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $37.77 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $33.75 | 2019 | |
| Bard Access Systems, INC. | $26.06 | 2019 | |
| Atricure, INC. | $15.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.36 | 2019 | |
| Merck Sharp & Dohme LLC | $14.20 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Weingarden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.